SCHEMBL29574073

SCHEMBL29574073

CC1(C)O[C@H]2[C@H](n3cnc4c(NCC(F)F)nc(Cl)nc43)[C@H]3C[C@@]3(CF)[C@H]2O1

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ HTR2B P41595 17/20 0.51
▸ ADORA1 P30542 13/20 0.51
▸ ADORA3 P0DMS8 9/20 0.51
▸ HRH2 P25021 2/20 0.51
▸ HTR5A P47898 1/20 0.51
▸ HTR2C P28335 14/20 0.49
▸ SLC6A3 Q01959 3/20 0.49
▸ HTR1D P28221 2/20 0.49
▸ ADRA2B P18089 1/20 0.49
▸ ADORA2A P29274 7/20 0.46
▸ TMIGD3 P0DMS9 6/20 0.46
▸ TSPO P30536 2/20 0.42
▸ TMEM97 Q5BJF2 1/20 0.42
▸ ADRA2C P18825 1/20 0.42
▸ HTR2A P28223 1/20 0.42
▸ OPRM1 P35372 1/20 0.42
▸ CHRM3 P20309 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29573875 0.90 HRH2 (0.53) HTR2BADORA1ADORA3HRH2HTR5A
SCHEMBL31350147 0.86 HTR2B (0.70) HTR2BADORA1ADORA3HRH2HTR5A
SCHEMBL31350105 0.84 HTR2B (0.71) HTR2BADORA1ADORA3HRH2HTR5A
SCHEMBL31350257 0.84 HTR2B (0.71) HTR2BADORA1ADORA3HRH2HTR5A
SCHEMBL29573781 0.82 HTR2B (0.73) HTR2BADORA1ADORA3HRH2HTR2C
SCHEMBL29574455 0.81 ADORA3 (0.55) HTR2BADORA1ADORA3HTR2CADORA2A
SCHEMBL29573969 0.79 HRH2 (0.54) HTR2BADORA1ADORA3HRH2HTR5A
SCHEMBL29574436 0.78 ADORA1 (0.57) HTR2BADORA1ADORA3HTR2CSLC6A3
SCHEMBL31350070 0.77 HTR2B (0.71) HTR2BADORA1ADORA3HRH2HTR5A
SCHEMBL19415065 0.77 HTR2B (0.55) HTR2BADORA1ADORA3HRH2HTR5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4196219-A1 A3 ADENOSINE RECEPTOR AGONISTS FOR USE IN MEDICINE Biointervene, Inc. (US) 2023-06-21 — — EP disclosed
WO-2022040241-A1 A3 ADENOSINE RECEPTOR AGONISTS FOR USE IN MEDICINE BIOINTERVENE, INC. (US) 2022-02-24 — — WO disclosed
Send feedback